Michael Halpin
Chief Operating Officer bij VERICEL CORPORATION
Vermogen: 49 367 $ op 31-03-2024
Profiel
Michael Halpin is currently the Chief Operating Officer at Vericel Corp.
Prior to his current position, he held the role of Vice President-North American Region Regulatory at Genzyme Corp.
from 2002 to 2017.
He also worked as Vice President-North American Region Regulatory at Sanofi Corp.
Mr. Halpin completed his undergraduate and graduate degrees at the University of Virginia.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
VERICEL CORPORATION
0.00% | 11-03-2024 | 949 ( 0.00% ) | 49 367 $ | 31-03-2024 |
Actieve functies van Michael Halpin
| Bedrijven | Functie | Begin |
|---|---|---|
| VERICEL CORPORATION | Chief Operating Officer | 15-06-2019 |
Eerdere bekende functies van Michael Halpin
| Bedrijven | Functie | Einde |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | - |
| Sanofi Corp. | Corporate Officer/Principal | - |
Opleiding van Michael Halpin
| University of Virginia | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| VERICEL CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Sanofi Corp. |
